MA50403A - Promédicaments de dantrolène et leurs procédés d'utilisation - Google Patents

Promédicaments de dantrolène et leurs procédés d'utilisation

Info

Publication number
MA50403A
MA50403A MA050403A MA50403A MA50403A MA 50403 A MA50403 A MA 50403A MA 050403 A MA050403 A MA 050403A MA 50403 A MA50403 A MA 50403A MA 50403 A MA50403 A MA 50403A
Authority
MA
Morocco
Prior art keywords
dantrolene
medicinal products
use procedures
procedures
medicinal
Prior art date
Application number
MA050403A
Other languages
English (en)
Inventor
Adrian Hepner
Alyssa Larson
Charles Wescott
Original Assignee
Eagle Res Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Res Labs Limited filed Critical Eagle Res Labs Limited
Publication of MA50403A publication Critical patent/MA50403A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
MA050403A 2017-10-20 2018-10-19 Promédicaments de dantrolène et leurs procédés d'utilisation MA50403A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762575124P 2017-10-20 2017-10-20
US201862674422P 2018-05-21 2018-05-21

Publications (1)

Publication Number Publication Date
MA50403A true MA50403A (fr) 2021-04-28

Family

ID=64277793

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050403A MA50403A (fr) 2017-10-20 2018-10-19 Promédicaments de dantrolène et leurs procédés d'utilisation

Country Status (18)

Country Link
US (3) US11352347B2 (fr)
EP (2) EP3697779B1 (fr)
JP (2) JP7252963B2 (fr)
KR (1) KR102652642B1 (fr)
CN (1) CN111344286A (fr)
AU (2) AU2018351494C1 (fr)
BR (1) BR112020007858A2 (fr)
CA (1) CA3079558A1 (fr)
CO (1) CO2020006193A2 (fr)
ES (1) ES3016835T3 (fr)
IL (1) IL274045B2 (fr)
MA (1) MA50403A (fr)
MX (2) MX2020003400A (fr)
MY (1) MY201417A (fr)
SG (1) SG11202003452XA (fr)
UA (1) UA127738C2 (fr)
WO (1) WO2019079721A1 (fr)
ZA (1) ZA202002779B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3016835T3 (en) * 2017-10-20 2025-05-09 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
IL283061B2 (en) * 2018-11-27 2025-09-01 Eagle Res Labs Limited Use of dantrolene and dantrolene prodrugs for the treatment of radiation exposure
EP3771711A1 (fr) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Dérivés de pyrazole pour le contrôle des arthropodes
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome
US20230143775A1 (en) 2020-04-10 2023-05-11 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections
KR20230002371A (ko) 2020-04-10 2023-01-05 이글 파마슈티컬즈 인코포레이티드 SARS-CoV-2 감염증 치료 방법
EP4132517A1 (fr) 2020-04-10 2023-02-15 Eagle Pharmaceuticals, Inc. Méthodes de traitement d'infections virales

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4137402A (en) 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2008086492A1 (fr) 2007-01-11 2008-07-17 Xenoport, Inc. Formes galéniques orales à libération prolongée d'un promédicament de r-baclofène et procédés de traitement
EP2583670A1 (fr) * 2007-10-09 2013-04-24 US Worldmeds LLC Compositions de co-solvants et procédés servant à améliorer la fourniture d'agents thérapeutiques à base de dantrolène
US8536213B2 (en) * 2007-11-16 2013-09-17 Nektar Therapeutics Oligomer-dantrolene conjugates and related compounds
WO2009152205A1 (fr) 2008-06-10 2009-12-17 Meta Cosmetics, Llc. Compositions topiques comprenant des analogues de l’imidazolidinédione et leur utilisation pour traiter ou prévenir l’aspect des rides de la peau
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
US9193717B2 (en) 2011-10-13 2015-11-24 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
JP2016514685A (ja) 2013-03-15 2016-05-23 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 異常レベルのカルシウム放出からリアノジン受容体を安定化するための化合物
WO2014191837A2 (fr) 2013-05-06 2014-12-04 University Health Network Méthodes d'administration de dantrolène dans le traitement d'urgence des arythmies cardiaques
EP2994133A4 (fr) 2013-05-08 2016-11-16 Univ Howard Compositions et méthode de traitement des lésions neuronales de reperfusion ischémique
HUP1300720A2 (hu) 2013-12-12 2015-06-29 Univ Szegedi Gyógyászati készítmények sebgyógyulás elõsegítésére
WO2015182625A1 (fr) 2014-05-26 2015-12-03 国立大学法人京都大学 INHIBITEUR DE L'ACTIVITÉ Ras ET SON UTILISATION
WO2016077706A1 (fr) 2014-11-13 2016-05-19 Washington University Traitement du syndrome de wolfram et d'autres troubles de stress du réticulum endoplasmique
ES2898425T3 (es) 2015-10-20 2022-03-07 Braun Melsungen Ag Composición acuosa que comprende dantroleno
ES3016835T3 (en) * 2017-10-20 2025-05-09 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
SE542780C2 (en) 2018-09-15 2020-07-07 Coloreel Group AB A system and method for in-line treatment of thread

Also Published As

Publication number Publication date
CO2020006193A2 (es) 2020-08-21
EP3697779A1 (fr) 2020-08-26
RU2020116367A3 (fr) 2021-11-26
IL274045A (en) 2020-06-30
AU2023278113A1 (en) 2024-01-04
US20200239455A1 (en) 2020-07-30
WO2019079721A1 (fr) 2019-04-25
EP4574832A3 (fr) 2025-09-17
EP3697779B1 (fr) 2025-03-05
IL274045B1 (en) 2023-05-01
US20250145593A1 (en) 2025-05-08
MX2020003400A (es) 2020-09-18
UA127738C2 (uk) 2023-12-20
US12269815B2 (en) 2025-04-08
CA3079558A1 (fr) 2019-04-25
ES3016835T3 (en) 2025-05-09
AU2018351494C1 (en) 2025-10-23
ZA202002779B (en) 2023-10-25
US11352347B2 (en) 2022-06-07
KR102652642B1 (ko) 2024-04-01
CN111344286A (zh) 2020-06-26
JP2021500405A (ja) 2021-01-07
JP7252963B2 (ja) 2023-04-05
AU2023278113B2 (en) 2025-09-04
RU2020116367A (ru) 2021-11-22
KR20200072514A (ko) 2020-06-22
IL274045B2 (en) 2023-09-01
AU2018351494A1 (en) 2020-04-30
US20220324850A1 (en) 2022-10-13
BR112020007858A2 (pt) 2020-10-27
AU2018351494B2 (en) 2023-09-14
SG11202003452XA (en) 2020-05-28
MX2023010501A (es) 2023-09-20
EP4574832A2 (fr) 2025-06-25
JP2023061949A (ja) 2023-05-02
MY201417A (en) 2024-02-21

Similar Documents

Publication Publication Date Title
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3678681A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
EP3717636A4 (fr) Variants de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3684423A4 (fr) Virus adéno-associé à variant de capsides et leurs procédés d'utilisation
MA50403A (fr) Promédicaments de dantrolène et leurs procédés d'utilisation
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation